Operating Income (Loss) in USD of Fulgent Genetics, Inc. from 2014 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Fulgent Genetics, Inc. quarterly/annual Operating Income (Loss) history and change rate from 2014 to Q3 2025.
  • Fulgent Genetics, Inc. Operating Income (Loss) for the quarter ending 30 Sep 2025 was -$15.4M, a 10.1% increase year-over-year.
  • Fulgent Genetics, Inc. Operating Income (Loss) for the twelve months ending 30 Sep 2025 was -$71M, a 66% increase year-over-year.
  • Fulgent Genetics, Inc. annual Operating Income (Loss) for 2024 was -$73.9M, a 62.2% increase from 2023.
  • Fulgent Genetics, Inc. annual Operating Income (Loss) for 2023 was -$196M, a 210% decline from 2022.
  • Fulgent Genetics, Inc. annual Operating Income (Loss) for 2022 was $179M, a 73.6% decline from 2021.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Change (%)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Change (%)

Fulgent Genetics, Inc. Quarterly Operating Income (Loss) (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 -$71M -$15.4M +$1.73M +10.1% 01 Jul 2025 30 Sep 2025 10-Q 07 Nov 2025
Q2 2025 -$72.7M -$19.7M -$807K -4.27% 01 Apr 2025 30 Jun 2025 10-Q 01 Aug 2025
Q1 2025 -$71.9M -$19.8M +$2M +9.19% 01 Jan 2025 31 Mar 2025 10-Q 02 May 2025
Q4 2024 -$73.9M -$16.1M +$135M +89.3% 01 Oct 2024 31 Dec 2024 10-K 28 Feb 2025
Q3 2024 -$209M -$17.1M -$17.3M -8081% 01 Jul 2024 30 Sep 2024 10-Q 07 Nov 2025
Q2 2024 -$192M -$18.9M +$892K +4.51% 01 Apr 2024 30 Jun 2024 10-Q 01 Aug 2025
Q1 2024 -$193M -$21.8M +$3.03M +12.2% 01 Jan 2024 31 Mar 2024 10-Q 02 May 2025
Q4 2023 -$196M -$151M -$115M -313% 01 Oct 2023 31 Dec 2023 10-K 28 Feb 2025
Q3 2023 -$81M $214K -$138K -39.2% 01 Jul 2023 30 Sep 2023 10-Q 08 Nov 2024
Q2 2023 -$80.8M -$19.8M -$32.6M -255% 01 Apr 2023 30 Jun 2023 10-Q 02 Aug 2024
Q1 2023 -$48.2M -$24.8M -$227M -112% 01 Jan 2023 31 Mar 2023 10-Q 03 May 2024
Q4 2022 $179M -$36.6M -$187M -124% 01 Oct 2022 31 Dec 2022 10-K 28 Feb 2023
Q3 2022 $366M $352K -$159M -99.8% 01 Jul 2022 30 Sep 2022 10-Q 03 Nov 2023
Q2 2022 $525M $12.8M -$86.1M -87.1% 01 Apr 2022 30 Jun 2022 10-Q 04 Aug 2023
Q1 2022 $611M $202M -$65M -24.3% 01 Jan 2022 31 Mar 2022 10-Q 05 May 2023
Q4 2021 $676M $151M -$75M -33.2% 01 Oct 2021 31 Dec 2021 10-K 28 Feb 2023
Q3 2021 $751M $159M +$95.8M +151% 01 Jul 2021 30 Sep 2021 10-K 28 Feb 2023
Q2 2021 $655M $98.9M +$96.3M +3646% 01 Apr 2021 30 Jun 2021 10-K 28 Feb 2023
Q1 2021 $559M $267M +$269M 01 Jan 2021 31 Mar 2021 10-K 28 Feb 2023
Q4 2020 $290M $226M +$226M 01 Oct 2020 31 Dec 2020 10-K 28 Feb 2022
Q3 2020 $63.8M $63.5M +$62M +4110% 01 Jul 2020 30 Sep 2020 10-K 28 Feb 2022
Q2 2020 $1.83M $2.64M +$2.35M +795% 01 Apr 2020 30 Jun 2020 10-K 28 Feb 2022
Q1 2020 -$519K -$1.91M -$91K -4.99% 01 Jan 2020 31 Mar 2020 10-K 28 Feb 2022
Q4 2019 -$428K -$409K +$620K +60.3% 01 Oct 2019 31 Dec 2019 10-K 08 Mar 2021
Q3 2019 -$1.05M $1.51M +$2.36M 01 Jul 2019 30 Sep 2019 10-K 08 Mar 2021
Q2 2019 -$3.4M $295K +$1.3M 01 Apr 2019 30 Jun 2019 10-K 08 Mar 2021
Q1 2019 -$4.7M -$1.82M +$371K +16.9% 01 Jan 2019 31 Mar 2019 10-K 08 Mar 2021
Q4 2018 -$5.07M -$1.03M +$1.04M +50.3% 01 Oct 2018 31 Dec 2018 10-K 13 Mar 2020
Q3 2018 -$6.11M -$846K +$635K +42.9% 01 Jul 2018 30 Sep 2018 10-K 13 Mar 2020
Q2 2018 -$6.75M -$1M -$851K -567% 01 Apr 2018 30 Jun 2018 10-K 13 Mar 2020
Q1 2018 -$5.9M -$2.19M -$2.41M -1102% 01 Jan 2018 31 Mar 2018 10-K 13 Mar 2020
Q4 2017 -$3.48M -$2.07M -$3.33M -264% 01 Oct 2017 31 Dec 2017 10-K 22 Mar 2019
Q3 2017 -$153K -$1.48M -$786K -113% 01 Jul 2017 30 Sep 2017 10-K 22 Mar 2019
Q2 2017 $633K -$150K -$1.12M -115% 01 Apr 2017 30 Jun 2017 10-K 22 Mar 2019
Q1 2017 $1.75M $219K +$834K 01 Jan 2017 31 Mar 2017 10-K 22 Mar 2019
Q4 2016 $919K $1.26M +$8.6M 01 Oct 2016 31 Dec 2016 10-K 20 Mar 2018
Q3 2016 -$7.68M -$695K -$1.88M -159% 01 Jul 2016 30 Sep 2016 10-K 20 Mar 2018
Q2 2016 -$5.81M $970K +$223K +29.9% 01 Apr 2016 30 Jun 2016 10-K 20 Mar 2018
Q1 2016 -$6.03M -$615K -$1.02M -252% 01 Jan 2016 31 Mar 2016 10-K 20 Mar 2018
Q4 2015 -$5.01M -$7.34M 01 Oct 2015 31 Dec 2015 10-K 17 Mar 2017
Q3 2015 $1.18M 01 Jul 2015 30 Sep 2015 10-K 17 Mar 2017
Q2 2015 $747K 01 Apr 2015 30 Jun 2015 10-K 17 Mar 2017
Q1 2015 $405K 01 Jan 2015 31 Mar 2015 10-K 17 Mar 2017

Fulgent Genetics, Inc. Annual Operating Income (Loss) (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 -$73.9M +$122M +62.2% 01 Jan 2024 31 Dec 2024 10-K 28 Feb 2025
2023 -$196M -$374M -210% 01 Jan 2023 31 Dec 2023 10-K 28 Feb 2025
2022 $179M -$497M -73.6% 01 Jan 2022 31 Dec 2022 10-K 28 Feb 2025
2021 $676M +$386M +133% 01 Jan 2021 31 Dec 2021 10-K 28 Feb 2024
2020 $290M +$291M 01 Jan 2020 31 Dec 2020 10-K 28 Feb 2023
2019 -$428K +$4.64M +91.6% 01 Jan 2019 31 Dec 2019 10-K 28 Feb 2022
2018 -$5.07M -$1.59M -45.6% 01 Jan 2018 31 Dec 2018 10-K 13 Mar 2020
2017 -$3.48M -$4.4M -479% 01 Jan 2017 31 Dec 2017 10-K 22 Mar 2019
2016 $918K +$5.93M 01 Jan 2016 31 Dec 2016 10-K 20 Mar 2018
2015 -$5.01M -$4.02M -406% 01 Jan 2015 31 Dec 2015 10-K 17 Mar 2017
2014 -$990K 01 Jan 2014 31 Dec 2014 10-K 17 Mar 2017
* An asterisk sign (*) next to the value indicates that the value is likely invalid.